KeyBanc Capital Markets has revised its price target for ICU Medical (ICUI, Financial), reducing it from $209 to $191. Despite retaining an Overweight rating on the shares, the adjustment reflects growing economic uncertainties.
The analyst firm cited potential tariff impacts and an increased risk of recession as primary reasons for the adjustment. Although KeyBanc maintains a positive outlook on the general trends within the medical technology sector as it approaches the first quarter earnings announcements, these external economic factors have led to a more conservative valuation.
